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9Summary
Human cytomegalovirus (HCMV) is a member of the betaherpesviruses. It is a ubiqui-
tous virus, the seroprevalence of which varies between 30 to 100 % in different coun-
tries. Acquisition of the virus in the general population mainly occurs early in life. Trans-
mission of the virus can occur vertically or horizontally via direct contact with infectious
bodily fluids or blood. The virus can also be transmitted by blood products or transplanted
organs. After the primary infection, the virus will remain in a latent state in the host life-
long but may reactivate later. Infections in an immunocompetent individual are mainly
asymptomatic or mild, mononucleosis-like syndromes. However, in immunocompro-
mised patients, severe HCMV infections may occur.
HCMV is a significant pathogen in transplant patients causing symptomatic infections
and end-organ diseases which may, without antiviral treatment, be life-threatening. Many
risk factors for the development of symptomatic infection have been suggested. Viral load
has been shown to be a major factor in the development of HCMV disease. The assess-
ment of viral load has an important value in the diagnosis and monitoring of HCMV
infection, and also in the prevention and treatment strategies of HCMV disease with
antiviral drugs. Since the late 1980’s, the semi-quantitative CMV pp65 antigenemia as-
say has been a commonly used method for these purposes. Within recent years, the ap-
plications of nucleic acid amplification techniques, especially quantitative modifications
of PCR (polymerase chain reaction), have been developed for HCMV. PCR-based meth-
ods, both commercial and in-house applications, are widely used in clinical laboratories,
and their utility in the HCMV diagnostics of transplant patients is now evaluated.
In the present study, the value of a commercial quantitative PCR test in the diagnosis of
HCMV infection in organ transplant patients was investigated. The test was compared
with the pp65 antigenemia assay, and a good correlation between the tests was shown.
The clinical utility of quantitative PCR was further evaluated. The suitability of quanti-
tative PCR for the diagnosis of symptomatic infection was proven. In addition, quanti-
tative PCR was shown to have a clinical value in the monitoring of both asymptomatic
and symptomatic HCMV infection in individual liver and kidney transplant patients.
Also the response to the antiviral treatment was easily followed using the quantitative PCR
assay. The next step was to develop a real-time PCR based assay, because the need for faster
and more automated technique with a greater capacity for the quantitation of HCMV
load was obvious. The clinical value of the developed real-time assay was also shown in
the diagnosis and monitoring of HCMV infection in transplant patients.
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Review of the literature
1. Human cytomegalovirus
1.1. Virus structure and genome organization
Human cytomegalovirus (HCMV) is a member of the Betaherpesvirinae subfamily, which
belongs to the family Herpesviridae (Mocarski and Courcelle, 2001). Betaherpesviruses,
which also includes human herpesvirus 6 (HHV-6) and human herpesvirus 7 (HHV-7),
are more closely related to each other than to the other herpesviruses. HCMV is strictly
species specific, as are the other cytomegaloviruses. HCMV has a linear double-stranded
DNA genome of approximately 230 kbp encoding more than 200 proteins. The virion,
which is 150-200 nm in diameter, consists of an icosahedral capsid surrounded by a teg-
ument or matrix, which is further surrounded by a lipid-protein envelope. The viral ge-
nome is divided into two unique components, unique long (U
L
) and unique short (U
S
)
regions (Figure 1.). The unique regions are flanked by terminal (TR) and inverted repeat
(IR) sequences, U
L
 by TR
L
 and IR
L
, and U
S
 by IR
S
 and TR
S
, respectively. DNA sequence-
based analyses demonstrate a great genomic heterogeneity within HCMV worldwide.
The capsid of the virion is composed of seven proteins. The major (MCP) and minor
capsid proteins (mCP) are encoded by UL86 and UL85, respectively. The minor capsid
binding protein (mC-BP) is encoded by UL46 and the smallest capsid protein (SCP) by
UL48.5. Three assemblin protein –related proteins associate with capsids and are the
products of UL80, UL80a and UL80.5 genes. A tegument contains at least 25 proteins,
of which many are phosphorylated. The basic phosphoprotein (pp150) encoded by UL32
and lower matrix protein (pp65) encoded by UL83, are the most abundant proteins ex-
pressed during virus replication. The other prominent tegument proteins are ppUL99
(pp28), ppUL82 (pp71) and ppUL48 (huge tegument protein). Several transcriptional
transactivator proteins have also been localized to the tegument. The envelope consists
of two prominent glycoprotein complexes, a complex of dimers of glycoprotein B (gB),
encoded by UL55, and a complex of the gH, gL, and gO, encoded by UL75, UL115 and
UL74, respectively. These glycoprotein complexes are assumed to play an important role
in virus entry.
1.2. Virus replication
HCMV exhibits a restricted host range in cell culture. Although in vitro the most com-
monly used cells are primary differentiated human fibroblasts derived from skin or lung,
HCMV can also replicate in other cell types including endothelial and epithelial cells,
smooth muscle cells and leukocytes (Pass, 2001; Sinzger and Jahn, 1996). After the at-
tachment of the virus to the cell surface, fusion of the virion envelope and the cell mem-
brane occurs (Mocarski and Courcelle, 2001). The cellular receptor(s) for HCMV is still
unclear, but it has been suggested to be widely distributed in cells (Mocarski and Courcelle,
11
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2001). Epidermal growth factor receptor has recently been suggested to serve as a recep-
tor for HCMV (Wang et al., 2003). The virus capsid is rapidly transported to the cell
nucleus and, after the proteolysis of the capsid proteins, the viral DNA is released into
the nucleus.
Viral gene expression in productive replication occurs in a temporally ordered cascade
(Mocarski and Courcelle, 2001; Sinclair, 2000). Immediate-early (IE) gene expression is
first activated followed by early and late gene expression which ultimately leads to virus
assembly and release from the infected cells. The most abundantly expressed IE genes are
transcribed from the major IE (MIE) locus, located in the U
L
 region (Figure 1.). The gene
products of UL122/123, IE1 and IE2, are generated by differential splicing of a primary
transcript. The IE proteins are transactivators of gene expression and play an important
role in controlling both viral and cellular gene expression. One function of these proteins
is to optimise the cellular environment for viral replication and viral gene expression. The
expression of IE proteins is also crucial for the next step of the temporal cascade, correct
expression of early genes. This is followed by the expression of late genes. The early (E)
proteins are involved in the replication of the viral DNA, whereas late (L) gene expression
provides the structural proteins/glycoproteins of the viral capsid, tegument and envelope.
DNA replication, formation of capsids and packaging of viral DNA occur in the nucle-
us. Subsequently, nucleocapsids acquire a primary envelopment by budding at the nu-
clear membrane. They further mature through a de-envelopment/re-envelopment proc-
ess in the cytoplasm before leaving the cell via an exocytic-like pathway (Mettenleiter,
2002; Mocarski and Courcelle, 2001). The whole replication cycle of human CMV is
slow, requiring approximately 48-72 hours. The cytopathic effect in response to HCMV
is characteristically cell enlargement with intranuclear inclusions.
1.3. Epidemiology and transmission
HCMV is an ubiquitous virus and it infects humans of all ages. Acquisition of the virus
in the general population usually occurs early in life, mainly during the first two decades,
and often already during the first year. Based on sero-epidemiological studies, the sero-
prevalence varies between 30 % to 100 % in different countries (Ho, 1990). The great
seroprevalence and also early acquisition of the virus have been associated with lower
socioeconomic circumstances, developing countries and countries with crowded popu-
lations (Ho, 1990). However, in Scandinavian countries seroprevalence is as high as 60-
80 %, and in Finland even 70-80 %, despite good hygiene and a high socioeconomic level.
After the primary infection, which is usually asymptomatic or very mild in immunocom-
petent individuals, the virus will remain in a lifelong latent state in the host. Later in life,
the virus can reactivate or an individual can have a reinfection. Transmission of the virus
can occur vertically from mother to fetus or newborn, or horizontally from one individ-
ual to another (Griffiths and Emery, 1997). During primary infection, the virus is secreted
into the urine, saliva, semen and cervical secretions for weeks to months, as well as in-
termittently during reactivations and reinfections. Vertical transmission can occur
12
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transplacentally or perinatally. An intra-uterine infection is the result of maternal viremia
and perinatally acquired infection can occur at the time of delivery from infected mater-
nal genital secretions or later via breast milk. Later in life, infection usually occurs by close
contact via infected bodily fluids, e.g. from child to child or from child to susceptible
adult via saliva or urine. In the adult population, a major route of infection is sexual trans-
mission. HCMV can also be transmitted by blood transfusions or by organ or bone
marrow transplantations.
1.4. Pathogenesis
It has been suggested that epithelial cells of the upper alimentary, respiratory and geni-
to-urinary tracts can be the site of primary replication after the direct contact of infec-
tious virus and mucosal surface (Pass, 2001). In addition, it has been suggested that a fetus
can be infected hematogenously (Halwachs-Baumann et al., 1998; Hemmings et al.,
1998). In any case, once HCMV infection is established, leukocyte-associated and en-
dothelial cell-associated viremia appears to play an important role in the passage of the
virus between the various tissues of the host. Viremia may last for several weeks during
the primary infection. Hematogenous spreading typically results in the infection of duc-
tal epithelial cells at the initial site. HCMV can infect a wide range of tissues including
TRL IRL
UL US
TRSIRS
1 2 4 53
1 2 3 4
51 2 3
IE1
IE2
MIEP
UL122/UL123
Figure 1. Simplified structure of the CMV genome
(UL = unique long region, US = unique short region, TRL and TRS = terminal
repeat sequence, IRL and IRS = inverted repeat sequence). The most abundantly
expressed viral genes at immediate early time are transcribed from the major IE
locus (MIE), located in UL region (MIEP = major IE promotor). The primary
transcript is differentially spliced to generate two major proteins, IE1 and IE2.
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salivary glands, gastrointestinal tract, lung, liver, brain, kidney, spleen, pancreas, eye, heart,
adrenals, thyroid and genital tract and then replicate in diverse cell types, including fi-
broblasts, epithelial cells, macrophages, vascular smooth muscle and endothelial cells (Pass,
2001). HCMV is also suggested to infect the vascular wall and play a role in the devel-
opment of atherosclerosis (Bruggeman, 2000).
After the primary infection, long-term cellular and humoral immunity develops. The cell-
mediated immunity, including both natural killer cells and cytotoxic-T lymphocytes, plays
an important role in the control of HCMV infection (Mocarski and Courcelle, 2001).
Humoral immune response also develops but it has been suggested to be less important
in the control of HCMV infection (Mocarski and Courcelle, 2001). However, the im-
mune defence is unable to clear the virus completely from the host, and the virus remains
latent lifelong within the host cell. The ability of the virus to evade the host immune
system may be due to various HCMV gene products, which show sequence similarity to,
or functional relatedness with, host proteins. The proteins may have an ability to engage
host proteins, which lead to alterations in host immune responses (Beck and Barrell, 1988;
Mocarski, 2002; Reyburn et al., 1997). These proteins can interfere in classical or non-
classical major histocompatibility complex protein function, modify leukocyte migration,
activation and cytokine responses, or modulate host cell susceptibility to apoptosis.
HCMV can not usually be isolated from the blood of healthy individuals (Jordan, 1983).
However, transmission can occur via blood transfusion. The risk can be reduced by re-
moval of blood leukocytes before transfusion (de Graan-Hentzen et al., 1989; Lang et
al., 1977). Thus, latently infected blood leukocytes probably are an important reservoir
for transmission of the virus in organ transplantation and blood transfusion. Peripheral
blood mononuclear cells in the myeloid lineage have been mainly found to support la-
tent infection, instead of lymphocytes and polymorphonuclear leukocytes (Taylor-Wie-
deman et al., 1993; Taylor-Wiedeman et al., 1991). The viral genome is maintained as a
circular plasmid in the nucleus of these latently infected CD14+ monocytes (Bolovan-
Fritts et al., 1999). Viral DNA has also been detected in the early bone marrow haemat-
opoietic progenitors (CD34+ cells) (Mendelson et al., 1996; von Laer et al., 1995), and
the common precursors of dendritic and myeloid cells (CD33+/CD14+ and CD33+/
CD15+, along with the dendritic cell markers CD1a and CD10) (Hahn et al., 1998). It
has been suggested that HCMV is maintained in the myeloid progenitor cells when they
differentiate into peripheral blood mononuclear cells in the absence of lytic gene expres-
sion. This helps the virus to evade the host immune response. HCMV latency-associat-
ed transcripts have also been found in myeloid cells in both experimental and natural
infection, but the role of these transcripts is still unclear (Hahn et al., 1998; Jenkins et
al., 2004; Kondo et al., 1994; Kondo et al., 1996). Reactivation of a latent virus by allo-
geneic stimulation of peripheral blood mononuclear cells has been demonstrated (Sod-
erberg-Naucler et al., 1997). Differentiation of latently infected monocytes into macro-
phages by activation of the immune response, seems to lead to virus reactivation and
productive infection (Jarvis and Nelson, 2002; Soderberg-Naucler et al., 1997; Taylor-
14
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Wiedeman et al., 1994). Activation of cytokines and signal transduction pathways have
been suggested to play an important role in reactivation of the virus (Fietze et al., 1994;
Ritter et al., 2000). The differentiation state of the cell seems to be critical for the silenc-
ing of IE gene expression and thus for the maintenance of latency.
In immunocompetent individuals, primary infection (and also reactivation/reinfection)
usually remains asymptomatic or results in benign clinical symptoms such as fever, ele-
vated levels of transaminases and/or mononucleosis syndrome. Severe clinical symptoms
are observed in congenital infections, and among immunocompromised patients (such
as transplant recipients and AIDS-patients) (Griffiths and Emery, 1997), in whom
HCMV infections are an important factor for developing HCMV-associated disease.
2. Human cytomegalovirus infections in organ
transplant patients
2.1. Clinical manifestations
The updated definitions of CMV infection and disease have recently been developed and
published (Ljungman et al., 2002). “CMV infection” is defined as the isolation of cytome-
galovirus or detection of viral proteins or nucleic acid in any body fluid or tissue speci-
men. The minimum requirements for definition of CMV disease are the documented
presence of fever, the presence of neutropenia or thrombocytopenia, and the detection
of CMV in the blood. An end-organ disease needs documented organ involvement by
CMV.
Many risk factors have been reported for the development of symptomatic HCMV in-
fection in organ transplant recipients. Viral load has been shown to be a major factor in
the pathogenesis of HCMV (Cope et al., 1997; Emery, 1999; Hassan-Walker et al., 1999).
Traditionally primary infections have been associated with the more severe forms of dis-
ease than reactivations or reinfections, i.e. the recipients who are HCMV-negative (R-)
and obtain an organ from HCMV-positive donor (D+) (Gorensek et al., 1990; Hassan-
Walker et al., 1999; Rubin, 1990). The type and intensity of immunosuppressive thera-
py are of primary importance. Administration of anti-thymocyte antibodies and rejec-
tion treatment with high doses of agents depressing cell-mediated immunity are a risk
factor (Eckhoff et al., 1998; Emery et al., 2000a; Hibberd et al., 1992; Mathew, 1998;
Portela et al., 1995; Rubin, 1990). The other factors known to have an influence include
the donor-recipient HLA matching and the type and amount of blood products used (Sia
and Patel, 2000). In general, the incidence of HCMV disease varies among type of trans-
plantation. Lung and heart-lung recipients (50-80 %) as well as pancreas and kidney-
pancreas recipients (50 %) have a greater risk of developing the disease than do heart,
liver and kidney recipients (8-35 %) (Ljungman, 2002; van der Bij and Speich, 2001).
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The symptoms of HCMV infection in immunocompromised patients usually include
prolonged fever, the presence of leukopenia and/or thrombocytopenia, and increased levels
of serum transaminases. In addition, HCMV may also cause severe end-organ diseases,
such as hepatitis, gastrointestinal infections and pneumonitis (Patel and Paya, 1999),
which may be life-threatening without antiviral treatment. HCMV infection of the trans-
planted organ may be an additional complication, which represents itself as impaired graft
function.
In addition to direct consequences, various indirect effects caused by HCMV have been
suggested (Fishman and Rubin, 1998; Rubin, 1990). Many clinical studies have shown
an association between HCMV infection and acute or chronic rejection in heart, kidney,
liver and lung transplantation (Evans et al., 2000; Grattan et al., 1989; Koskinen et al.,
1993a; Kroshus et al., 1997; Lautenschlager et al., 1997; Luckraz et al., 2003; Pouteil-
Noble et al., 1993; Reinke et al., 1994; Tong et al., 2002; Valantine, 1999). HCMV in-
fection has been proven to be a risk factor for allograft atherosclerosis and rate of graft
loss in heart transplantation (Grattan et al., 1989; Valantine, 1999). However, the im-
pact of HCMV on chronic rejection in other organs is suggestive but not conclusive, and
the opinions are still controversial (Cainelli and Vento, 2002; Lautenschlager, 2003). In
addition to transplant rejection, HCMV is a risk factor for other opportunistic infections,
such as bacterial and fungal infections (George et al., 1997; Husain et al., 2003) and has
also been associated with other viruses, such as HHV-6, HHV-7 and HCV (Dockrell et
al., 1997; Humar et al., 2002b; Lautenschlager et al., 2002; Paya, 1999; Razonable and
Paya, 2002).
2.2. Prevention and treatment of HCMV disease
Since primary infections are more likely to cause disease than reactivation/reinfection, the
patients whose serostatus is defined as D+/R- are at the highest risk of developing dis-
ease. Therefore, the determination of HCMV serostatus of an organ donor and recipi-
ent pre-transplantation is important. Also, leukocyte free blood products are used for
transplant patients. There is no effective vaccine against HCMV.
Before the development of suitable antiviral drugs against HCMV, a reduction in the
immunosuppressive regimen was used to prevent HCMV disease in transplant patients.
However, this often led to an increased incidence of graft rejection (Sia and Patel, 2000).
HCMV-immunoglobulins were also used then. Currently, good availability of antiviral
agents allows maintenance of the level of immunosuppression required to prevent graft
rejection.
Two different strategies, prophylaxis and pre-emptive therapy, are used for the preven-
tion of symptomatic HCMV infection after transplantation. In prophylaxis, antiviral
drugs are administered before any evidence of the virus, and in pre-emptive therapy, an-
tiviral drugs are administered when there is laboratory evidence of active but asympto-
matic infection.
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The antiviral strategies for treatment and prevention of HCMV disease are outlined in
more detail below.
2.2.1. Treatment of the disease
The three antiviral drugs that are currently licensed for the treatment of HCMV infection are
ganciclovir (GCV), foscarnet and cidofovir. Ganciclovir is the drug of choice in the treatment
of symptomatic infections. Ganciclovir is a specific nucleoside analog which first is phospho-
rylated before it gains antiviral activity (Littler et al., 1992; Sullivan et al., 1992). The initial
phosphorylation is mediated by virus encoded phosphotransferase (product of UL97). The
monophosphate form is further phosphorylated by the host’s cellular kinases into the active
triphosphate form, which inhibits viral DNA polymerase by competing with deoxyguanos-
ine triphosphate (Noble and Faulds, 1998). For the treatment of HCMV disease, ganciclovir
is administered intravenously (i.v.) for at least two weeks.
Intravenous foscarnet may be used under conditions of failure of ganciclovir treatment,
ganciclovir resistance, or excessive side effects, such as leukopenia (Crumpacker, 1996;
Noble and Faulds, 1998). Foscarnet is an inorganic pyrophosphate analog and directly
inhibits viral DNA polymerase (Chrisp and Clissold, 1991; Crumpacker, 1992). How-
ever, foscarnet is nephrotoxic, which limits its use in kidney transplantation. Intravenous
cidofovir may also be used, but experience of this agent in solid organ recipients are still
very limited. Cidofovir is a cytosine analog which does not require the virus encoded
phosphotransferase activity. Instead host cellular enzymes carry out the phosphorylations
needed for activation (Lalezari et al., 1995; Snoeck et al., 1988).
Valganciclovir, a pro-drug of ganciclovir, is a new promising compound which is admin-
istered orally and has an increased bioavailability compared to that of oral ganciclovir
(Pescovitz et al., 2000). Nowadays valganciclovir is used in therapy of HCMV disease,
however, more clinical trials are needed. The HCMV hyperimmunoglobulin may also
be used in some patient groups in combination with antiviral drugs, e.g. lung transplant
patients with HCMV pneumonia (Patel and Paya, 1999; Zamora, 2001).
2.2.2. Prophylaxis
Prophylaxis consists of administration of antiviral drugs, immediately after transplanta-
tion, either to all transplant recipients or only to those who are at the highest risk for the
HCMV disease, such as seronegative recipients receiving seropositive organ or patients
who are treated with anti-T-lymphocyte antibodies. The practice and guidelines for pro-
phylactic therapy vary widely, depending on the patient population and the transplant
center (Batiuk et al., 2002; Patel et al., 1996). Also hyperimmunoglobulin in combina-
tion with ganciclovir has been used in certain patient groups, e.g. lung transplant recip-
ients (Weill et al., 2003).
17
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The first antiviral drug used for prophylaxis was high-dose oral acyclovir, an analog of
deoxyguanosine. The efficacy of oral acyclovir has been demonstrated in studies show-
ing reductions in the incidence of HCMV disease compared with no treatment or pla-
cebo (Balfour et al., 1989; Couchoud et al., 1998; Mollison et al., 1993). A pro-drug of
acyclovir, valacyclovir, has been found to be more effective than acyclovir for prevention
of HCMV disease (Fiddian et al., 2002; Lowance et al., 1999). Valacyclovir has increased
oral bioavailability compared to that of acyclovir (Weller et al., 1993), and in vivo it is
first converted to acyclovir. The action of acyclovir (valacyclovir) is dependent on phos-
phorylation, in which thymidine kinase is important (Talarico et al., 1999). However,
CMV does not encode this kinase (unlike herpes simplex and varicella zoster viruses), and
the phosphorylation, which may be allowed by UL97 product (Talarico et al., 1999) is
less specific. For this reason, these drugs are not potent enough for the treatment of
HCMV infection.
Currently, the most widely used and specific drug for HCMV prophylaxis is ganciclovir,
administered orally or intravenously. Intravenous ganciclovir has been proven to be a
potent prophylactic agent in many studies (Merigan et al., 1992; Paya, 2001; Winston
et al., 1995). The availability of the oral form has increased the use of this agent (Speich
et al., 1999; Winston and Busuttil, 2004; Yango et al., 2003), although the bioavailabil-
ity of oral ganciclovir is lower when compared to that of intravenous ganciclovir. A pro-
drug of ganciclovir, valganciclovir, is a new, promising option also for prophylaxis. The
drug is effectively absorbed and it is nowadays widely used although the published re-
ports are still limited (Lake, 2003; Paya et al., 2004).
Although the efficacy of prophylaxis has been proven in many studies, there are still some
controversial issues. It has been suggested that prophylaxis may only delay the develop-
ment of HCMV disease in some patients (Brennan et al., 1997; Emery, 2001). Long term
and/or sub-optimal antiviral therapy may also induce resistant HCMV strains (Chou,
2001; Drew, 2000). Also the fact that prophylaxis exposes all patients to potentially tox-
ic drugs may diminish the utility of this approach (Emery, 2001). In addition, although
the prophylaxis strategy has been found as a cost-effective intervention against HCMV
(Das, 2003; Legendre et al., 2000), the surveillance strategies may be less costly (Emery,
2001; Singh, 2001).
2.2.3. Pre-emptive therapy
The advantage of pre-emptive therapy is the targeting of antiviral drugs only to those
patients who have laboratory evidence of active HCMV infection. This minimises the
number of patients who are exposed to antiviral drugs. Currently, the drug of choice for
pre-emptive therapy is ganciclovir. Recent studies have shown the efficacy of pre-emp-
tive therapy by the low rate of HCMV disease in different patient groups (Daly et al., 2002;
Sagedal et al., 2003; Torre-Cisneros et al., 2002). The effectiveness of pre-emptive therapy
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has also been proven in a randomized, placebo-controlled trial in liver transplant patients,
in which pre-emptive therapy was reported to decrease HCMV disease (Paya et al., 2002).
In the future, the effectiveness of new oral antiviral agents comparable or superior to in-
travenous ganciclovir (e.g. valganciclovir) remains to be seen.
In pre-emptive therapy only patients who have laboratory evidence of an active HCMV
infection are treated with antiviral drugs. Therefore, the diagnostic test should predict
impending symptomatic infection sufficiently early. In addition, because pre-emptive
therapy requires frequent surveillance of all patients, the test should also be specific as
well as rapid and easy to perform. Since viral load has been shown to be a major factor
in the pathogenesis of HCMV (Cope et al., 1997; Emery, 1999; Hassan-Walker et al.,
1999), quantitative measurements have been considered to have greater clinical value in
a pre-emptive therapy strategy. Various diagnostic methods, virological and/or DNA/
RNA-based, may be used for this purpose (Daly et al., 2002; Gerna et al., 2003; Grossi
et al., 1996; Sagedal et al., 2003; Sia and Patel, 2000).
2.2.4. Drug resistance
The occurrence of antiviral drug resistant HCMV strains have been documented also
among organ transplant patients (Isada et al., 2002; Limaye, 2002; Limaye et al., 2002;
Lurain et al., 2002). The major risk factors for drug resistance include the long duration
of drug exposure and high amounts of viral load (Chou, 2001; Drew, 2000). These fac-
tors are most prevalent in patients with primary infection, i.e. in D+/R- population, in
which resistance has most often been observed (Rosen et al., 1997; Singh, 2001). The
mutations in both the viral phosphotransferase gene (UL97) and the viral polymerase gene
(UL54), may confer antiviral drug resistance in HCMV. The mutations of the UL97
coding sequence, which may confer resistance only to ganciclovir, occur mainly in the
region including codons 460-607 (Chou et al., 1995; Hanson et al., 1995; Lurain et al.,
1994). The more rare mutations in the UL54 coding sequence may confer resistance to
any or all of the three most commonly used drugs (ganciclovir, foscarnet or cidofovir)
(Cihlar et al., 1998a; Cihlar et al., 1998b; Mousavi-Jazi et al., 2003). Mutations in UL54
appear to occur in regions between codons 300 and 1000, and they are often accompa-
nied by mutations in UL97, showing higher levels of resistance to ganciclovir with pos-
sible cross-resistance to foscarnet and/or cidofovir (Jabs et al., 2001).
Management of ganciclovir resistant HCMV infections is difficult. Increased dosages of
ganciclovir in combination with HCMV hyperimmunoglobulin and reduction of immu-
nosuppression, or combination therapy with ganciclovir and foscarnet have been used
(Limaye, 2002; Mylonakis et al., 2002). New drugs are also under development, many
of which have different targets than currently available DNA polymerase inhibitors (De
Clercq, 2003; Emery and Hassan-Walker, 2002), but their suitability for clinical use will
be seen in the near future.
19
REVIEW OF THE LITERATURE
3. Laboratory diagnostics of HCMV in
transplant patients
An accurate and rapid diagnosis of HCMV in transplant patients is of utmost importance.
Different laboratory methods based on either serology or identification of virus/virus
components in clinical specimens are now available. Historically HCMV infection has
been detected by cytomegalic inclusion bodies in tissue specimens. The sensitivity of the
histological examination has been enhanced by using immunostaining or in situ hybrid-
ization (ISH). However, these techniques have limited usefulness with transplant patients
and they are mainly used for diagnosing HCMV in an organ involvement. Serological
testing is mainly limited to determination of serostatus of recipient and donor before
transplantation. It lacks sensitivity as an indicator of active HCMV infection in the post-
transplant period. The infectious HCMV virus can be isolated from various clinical sam-
ples by using conventional tube cell culture or more rapid shell vial culture methods. These
methods are time-consuming and cumbersome, and their sensitivity is relatively low,
which diminishes the usefulness of these tests in rapid diagnosis and in the monitoring
of HCMV infection in transplant recipients. Since the late 1980’s, the pp65 antigene-
mia test has been the most common method for the diagnosis of HCMV infection. Be-
cause of its quantitative nature, it has proven the clinical utility, not only in the diagno-
sis of HCMV infection, but also in guiding pre-emptive therapy, as well as in monitoring
the response to antiviral treatment. However, in recent years, the tendency has been to-
wards replacement of the antigenemia assay with PCR methods, especially with quanti-
tative modifications of PCR, and also with other nucleic acid amplification techniques.
3.1. Histological methods
Traditionally the recognition of cytomegalic inclusion bodies in histological specimens
has been used for the diagnosis. In organ specific HCMV infection, such as HCMV
pneumonitis or hepatitis, characteristic viral inclusions may be seen. The large inclusions
are intranuclear and have a characteristic owl-eye appearance in haematoxylin and eosin
stained tissue specimens. The positive results correlate well with active HCMV infection
of the organ, e. g. hepatitis, but the sensitivity of the histopathological finding is rela-
tively low (Colina et al., 1995; Mattes et al., 2000; Paya et al., 1989). Immunostaining
with specific polyclonal or monoclonal antibodies against HCMV antigens has increased
the sensitivity of the method compared to conventional staining (Barkholt et al., 1994;
Colina et al., 1995; Paya et al., 1990). However, false-negative results may occur because of
the focal and scarce distribution of HCMV positive cells in tissue samples (Colina et al., 1995).
ISH methods, described for the identification of viral DNA in infected cells, have also been
employed to improve the histological diagnosis of infection (Barkholt et al., 1994; Colina et
al., 1995; Einsele et al., 1989; Espy et al., 1991; Musiani et al., 1996; Paya et al., 1990). HCMV
specific probe, usually labelled by biotin, is used in these assays.
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Although the histological methods may have an important role in detecting HCMV or-
gan involvement, they are not suitable for the early diagnosis of HCMV infection. In
addition, these assays are very laborious, and biopsy specimens are only taken when an
end-organ disease is suspected.
3.2. Serology
Humoral response to primary HCMV infection is manifested by the production of IgG
and IgM antibodies. Thus a diagnosis of HCMV infection can be obtained indirectly
through serology. A variety of laboratory tests with different degrees of sensitivity have
been described for the measurement of HCMV antibodies in human sera. The methods
include complement fixation, indirect hemagglutination, latex agglutination, radioim-
munoassay, immunofluorescence and enzyme immunoassay (Mendez et al., 1999a; Sia
and Patel, 2000). In enzyme-linked immunosorbent (EIA) assays many different antigens
have successfully been used as targets for detecting specific antibody production (Monte
et al., 1996). EIA-based methods can be easily automated, they are fast and convenient
to perform. They usually have good sensitivity and they are also commercially available.
However, the rise in serum antibody levels is an insensitive sign of actual HCMV in-
fection in transplant patients (Halling et al., 2001; Marsano et al., 1990; Schmidt
et al., 1995; Tanabe et al., 1997; Tong et al., 1998). The seroprevalence is high and
the presence of IgG antibodies is only informative of the patient’s past history regard-
ing HCMV infection. Furthermore, there is a time lag between primary infection and
IgM antibody production (IgM level can remain undetectable because of delayed
seroconversion owing to immunosupressive agents), and IgM antibodies can also
persist for a long time after infection in some healthy individuals. The results of the
serological tests can also be confused by blood transfusions and/or antibody based
therapy. Furthermore, increase or decrease in antibody levels, in general, does not
provide an actual diagnosis of HCMV infection in the immunosuppressed patient
population, due to frequent reactivations of the virus. Therefore serology has a lim-
ited diagnostic value in the transplant patient group.
Nevertheless, HCMV IgG antibody testing has a significant role in the evaluation of organ
and recipient prior to transplantation. Since the solid organ recipient who belongs to the
D+/R- group is considered to have the highest risk for the development of symptomatic
HCMV infection (Ljungman, 2002; Razonable et al., 2001b), it is important to identi-
fy the recipients and donors that have been previously infected.
3.3. Viral culture
Infectious virus can be isolated from various clinical materials, such as bodily secretions,
tissue or peripheral blood, in cell cultures which are permissive for HCMV replication.
Human fibroblast cell cultures, obtained from the foreskin or from the embryonic lung
tissues, have been used for conventional and shell vial methods for the isolation of HCMV
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(Mendez et al., 1999a). In conventional viral isolation methods, commonly used in ear-
lier times, determination of viral replication is based on typical cytopathic effects (CPE)
produced by HCMV. The time required for the development of CPE usually varies from
2 to 4 weeks, even up to six weeks.
Several less time-consuming methods have been developed for the isolation of infectious
virus (Mendez et al., 1999a; Sia and Patel, 2000). One of the most commonly used rap-
id method is the shell vial culture (Gleaves et al., 1984). In this method, for the improve-
ment of absorption of the virus, the specimen is centrifuged onto the cell culture. Fibrob-
lasts monolayers cultured in vials containing coverslips are used. These shell vial culture
methods utilize indirect immunofluorescence to detect the immediate-early (IE) viral
antigen after incubation of culture for one to three days (Lautenschlager et al., 1989).
The isolation of HCMV from the blood or target organ specimen by cell culture meth-
ods has a high correlation with disease. However, the relatively low sensitivity of detec-
tion of the virus in blood samples compared to nucleic acid-based and antigenemia meth-
ods, limits the use of these assays in the diagnosis and monitoring of HCMV infection
in transplant patients (Badley et al., 1996; Evans et al., 1999; van der Bij et al., 1988;
Wirgart et al., 1996).
Isolation of the virus from peripheral sites (such as urine or saliva) may be used to dem-
onstrate asymptomatic shedding of HCMV in the throat or urinary tract. On the other
hand, viral culture may be helpful in detecting HCMV from bronchoalveolar lavage (BAL)
or biopsy specimens in the organ specific infection. Nevertheless, detection of the virus
from the blood of immunocompromised patient is a sign of viremia and is always con-
sidered as a serious finding. Furthermore, positive virus isolation from any site of a se-
ronegative recipient is a clear indication of primary infection, which may rapidly progress
to a severe disease. However, viral culture is a qualitative method with a limited role in
the diagnosis of HCMV infection.
3.4. Antigen detection
The antigenemia assay, first described by professor The and his associates (van den Berg
et al., 1989; van der Bij et al., 1988), has been a major advance in the diagnosis of HCMV
infection in transplant patients. In this test, monoclonal antibodies to pp65 (UL83)
(Depto and Stenberg, 1989; Gerna et al., 1992; Grefte et al., 1992), the lower matrix
protein, are used for the direct immunostaining of blood polymorphonuclear leukocytes
(PMNL). However, it has been shown that the pp65 antigen in PMNLs is not a direct
indication of virus replication in vivo, since the virus and viral material detected in PMNLs
are transferred from other infected cells, e.g. endothelial cells, mainly by microfusion
events (Gerna et al., 2000). Nevertheless, the pp65 antigenemia assay has been success-
fully used in the diagnosis of HCMV in transplant patients since the late 1980’s.
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The pp65 antigenemia assay consists of numerous steps, including isolation of PMNL,
fixation, immunostaining, and microscopic evaluation and quantitation (The et al., 1995;
The et al., 1990; van den Berg et al., 1989). Dextran sedimentation or direct erythro-
cyte lysis can be used for isolation of leukocyte populations of blood. The isolated leu-
kocytes are then cytocentrifuged onto glass slides and indirect immunoperoxidase or
immunofluorescense staining is used for immunodetection of the HCMV antigen. Af-
ter microscopic evaluation, quantitative results are expressed as the number of HCMV-
positive leukocytes per number of cells evaluated, usually per 50 000 or 200 000 leuko-
cytes. The whole process can be performed within one day.
The antigenemia assay is more sensitive than cell culture methods in detecting HCMV
in the blood (Landry and Ferguson, 1993; van den Berg et al., 1991; van der Bij et al.,
1988). It is also highly specific for HCMV but a positive result does not always predict
the onset of symptomatic infection (Landry and Ferguson, 1993; Sia and Patel, 2000;
Tanabe et al., 1997). Nevertheless, when using the test in a quantitative manner, the as-
say can be used to predict and diagnose HCMV infection: at least, a higher degree of
antigenemia is correlated with symptomatic disease, as has been shown by many groups
(Hadaya et al., 2003; Humar et al., 1999; Kim et al., 2003; van den Berg et al., 1991;
van den Berg et al., 1989).
One disadvantage of the antigenemia assay is that the blood samples should be processed
within a certain time, preferably within six hours, for optimal results (Boeckh et al., 1994;
Schafer et al., 1997). In addition, though there have been attempts to simplify the method
(Gratacap-Cavallier et al., 2003; Ho et al., 1998), it is still quite time-consuming and
laborious, at least with large specimen numbers. The automation of the test is also diffi-
cult because of the number of steps and the subjective evaluation of the infected leuko-
cytes. Although there have been attempts to standardize the assay (Gerna et al., 1998;
The et al., 1995; Verschuuren et al., 1999), there are a number of various in-house and
commercial modifications available. This makes comparison of the results between dif-
ferent centers difficult. The clinically significant threshold of the number of positive leu-
kocytes seems to vary also among different types of transplant populations (Baldanti et
al., 1998; Razonable et al., 2002b; Sia and Patel, 2000). In any case, the pp65 antigene-
mia test has shown its clinical utility in the diagnosis of HCMV infection, in guiding of
pre-emptive therapy, and also in the monitoring of response to antiviral treatment (Bal-
danti et al., 1998; Grossi et al., 1996; Kim et al., 2003; Kusne et al., 1999; van den Berg
et al., 1993).
3.5. Nucleic acid amplification methods
The widespread introduction of the application of nucleic acid amplification technolo-
gies has been the most important improvement in HCMV diagnostics in the past dec-
ade. The most frequently used methods are based on PCR detecting HCMV DNA (or
RNA) in whole blood or in different blood compartments. Both qualitative and quanti-
tative assays have been used. However, understanding of the correlation between viral loads
and clinical symptoms has diminished the significance of qualitative methods. Different
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kind of quantitative PCR assays, both in-house and commercial ones, have been em-
ployed. The in-house assays, based on competitive PCR, are usually technically compli-
cated. Commercial and real-time based applications, which are more convenient and fast-
er, are more widely used at present. Also other nucleic acid-based techniques, such as
nucleic acid sequence based amplification (NASBA) and signal amplification (Hybrid
Capture System), have successfully been used in the detection of viral mRNA or DNA,
respectively.
3.5.1. Principles of PCR
The invention of PCR has been one of the major advances in the area of molecular-based
methods (Mullis and Faloona, 1987; Saiki et al., 1988; Saiki et al., 1985). PCR is a tech-
nique which allows a specific target DNA fragment to be exponentially amplified in vit-
ro in a very easy way. In theory, a millionfold increase in yield of the desired target se-
quence can be achieved in a few hours, or even faster nowadays. PCR utilises a pair of
oligonucleotides (primers), each hybridising to one strand of a double stranded DNA
(dsDNA) target. The primers flank the region that will be amplified. The hybridised
primer acts as a substrate for a thermostable DNA polymerase (most commonly derived
from Thermus aquaticus and called Taq polymerase) that synthesises a complementary
strand via the sequential addition of deoxyribonucleotides. The process includes repeti-
tive cycles of three steps, denaturation of dsDNA, annealing of the primers and exten-
sion of the DNA fragments, which are accomplished by cyclic temperature changes in
the reaction (Figure 2). The number of repetitive cycles varies usually from 25 to 50 in
PCR tests used for diagnostic purposes. In addition to suitable primers, template DNA,
polymerase enzyme, and deoxyribonucleotide mixture, optimal conditions for the en-
zyme are needed for successful PCR. If the starting material is RNA, a further step
with a reverse transcriptase (RT) enzyme is needed before amplification. This technique
is then referred to as RT-PCR. At present, various programmable thermal cyclers, which
vary in many technical aspects such as capacity and rapidity, are available for the perform-
ance of a PCR run.
Conventional detection of amplified DNA products relies on electrophoresis combined
with ethidium bromide staining. The sensitivity and specificity of the detection can be
improved using hybridisation methods either after, or instead of, electrophoresis. Tradi-
tionally, the detection has been performed after the completion of the PCR run, but the
recent development of real-time PCR instruments allows monitoring of the accumula-
tion of PCR products during the run.
3.5.2. Basics of quantitative PCR
PCR can also be used for the quantitation of nucleic acids. Until the introduction of real-
time PCR, competitive PCR (Gilliland et al., 1990; Siebert and Larrick, 1992) had been
the most common method to measure the amount of DNA or RNA in a clinical sam-
ple. In this technique, a reference (competitor), which is usually a synthetic nucleic acid
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cycle 1
cycle 2
cycles 3-40
a)
b)
c)
d)
e)
Figure 2. The principle of PCR
a) The double stranded template DNA is first denaturated at high temperature
(~ 94-96°C). b) The lower temperature of reaction allows the primers to hybridise
to the complementary sequences of the target DNA (~ 37-72°C). c) Extension
of the primers by Taq polymerase enzyme occurs at 72°C. d)-e) One cycle con-
sists of these three reactions in different temperatures. Cycles are repeated and
the amount of amplified sequence is increased exponentially.
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fragment with the same primer annealing sites as the specific target, is co-amplified with
the target of interest. After completion of PCR, amplification products of the specific tar-
get and of the competitor are separated on the basis of minor modifications in their se-
quences, and the ratio of their quantities is calculated. Successful quantitation is accom-
plished only if the specific conditions are met in the reactions, i.e. the target and
competitor sequences have to be amplified with equal efficiencies, which ensures that the
initial ratio of target to competitor remains constant through the amplification. The in-
itial amount of target DNA in a sample can be determined when the initial amount of
the competitor is known.
One drawback of competitive PCR is the narrow linear range of quantitation, 2-3 logs
at best, that can be achieved. In addition to this, in-house competitive quantitative meth-
ods are usually complicated and time-consuming, which has diminished their attractive-
ness in clinical laboratories. Availability of commercial competitive tests has improved the
situation for quantitative PCR.
In real-time PCR (also called kinetic PCR), the accumulation of the PCR products is
monitored continuously during the PCR run, compared with the end-point measure-
ments that quantitate the final PCR product. At present, several instruments are availa-
ble for real-time PCR, in which the accumulation of the product is monitored by meas-
uring the fluorescence in each cycle. The measured fluorescence is plotted against the cycle
number (Heid et al., 1996). The cycle number, in which the exponential amplification
(threshold cycle C
T
) is first detected over background, has an inverse linear relationship
to the amount of target in the initial reaction. Absolute quantitation of the amount of
target in the initial sample can be accomplished by measuring its C
T
 value and using the
external standard curve to determine the starting copy number of the target genome. This
system allows a very wide dynamic range of quantitation, at least 5-6 logs.
Currently, various chemistries for the detection of PCR products during real-time PCR
are available (Mackay et al., 2002). These can be classified into amplicon sequence spe-
cific or non-specific detection methods. The most commonly used detection methods in
the virus diagnostic assays are based on the use of specific fluorogenic oligoprobes. These
methods rely upon fluorescence resonance energy transfer (FRET), which is the interac-
tion of two fluorescent dyes. TaqMan probes (Holland et al., 1991), also called 5´ nu-
clease or hydrolysis oligoprobes, were the first ones used in special real-time instruments
(Heid et al., 1996). These probes are linear oligonucleotides that have a reporter fluores-
cent dye at the 5´ end and a quencher dye at the 3´ end. When the probe is intact, two
labels are close to each other and the quencher dye greatly reduces the light emission of
the reporter dye. During the extension phase of PCR, if the target is present, the probe
anneals downstream from one of the primer sites (Figure 3a) and is cleaved by the 5´
nuclease activity of Taq DNA polymerase as this primer is extended (Figure 3b). Cleav-
age removes the probe from the target, and at the same time also separates the reporter
dye from the quencher dye, allowing the light emission of the reporter dye to occur (Figure
3c). This light emission can be detected by a real-time instrument, for which the ABI
Prism 7000, 7700 or 7900HT sequence detection systems (Applied Biosystems) are the
most used ones at present. The other commonly used probes are hybridization probes,
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which have become the method of choice for the LightCycler real-time instrument (Ro-
che Molecular Biochemicals). In this technique, two adjacent probes are used, one labelled
with a 3´ fluorescein and the other with 5´ dye (Wittwer et al., 1997). When both oli-
goprobes are hybridized during the PCR process near to each other, FRET can occur
between the labels and the acceptor dye emits light.
R Q
R
Q
Q
R
a)
b)
c)
Figure 3. Stepwise representation of nuclease activity of Taq polymerase with
the 5´ nuclease oligoprobe during extension phase of PCR (R = reporter, Q
= quencher)
a) During of the extension phase the probe anneals downstream from one of the
primer sites. b) The probe is cleaved by the 5’ nuclease activity of Taq polymer-
ase as this primer is extended. c) Cleavage removes the probe from the target,
and at the same time also separates the reporter dye from quencher dye allow-
ing the light emission of reporter dye to occur.
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3.5.4. Qualitative PCR in the laboratory diagnostics of HCMV
Qualitative PCR has been proven to be more sensitive than antigenemia test or cell cul-
ture assay on the detection of HCMV infection (Cunningham et al., 1995; Evans et al.,
1998; Hiyoshi et al., 1997; Rowley et al., 1991; Weinberg et al., 2000). Despite extreme
sensitivity and specificity in detecting HCMV DNA, qualitative assays usually have a low
positive predictive value for symptomatic infection, at least when peripheral blood leu-
kocytes have been used as a specimen (Delgado et al., 1992; Gerna et al., 1991; Tanabe
et al., 1997). This is due to the capacity of these tests to detect HCMV DNA even in
the case of latent infection. It has also been reported that the demonstration of HCMV
DNA in plasma may correlate more closely with disease, and also with the antigenemia
test, than that in leukocytes or whole blood (Patel et al., 1994; Wolf and Spector, 1993;
Wolff et al., 1996). In any case, a negative PCR result strongly indicates against HCMV
infection, and a positive result in a seronegative person speaks for primary infection.
Several in-house protocols for the qualitative PCR detection of HCMV have been de-
scribed with wide variability in the performance (e.g. differences in nucleic acid extrac-
tion methods, target sequences, primers, instruments, amplification protocols, reagent
concentrations, detection methods) (Cunningham et al., 1995; Gerna et al., 1991; Rowley
et al., 1991; Wolf and Spector, 1993). This has made the results non-comparable between
different laboratories (Grundy et al., 1996). In addition, at least when using conventional
instruments for amplification and gel electrophoresis and hybridisation for detecting the
amplification products, these techniques are laborious and time-consuming. The use of
commercial assays (Hiyoshi et al., 1997) has simplified qualitative PCR technically, but
it has not removed the problem in its clinical use, i.e. the possible detection of latent
infection in seropositive recipients.
3.5.5. Quantitative PCR in the laboratory diagnostics of HCMV
The first developed in-house quantitative PCR tests were laborious methods, based on
the co-amplification of a DNA standard that competed with a target sequence using the
same primer sites (Barber et al., 1999; Boom et al., 1999; Cope et al., 1997; Mendez et
al., 1998b; Toyoda et al., 1997; Zipeto et al., 1993). Whilst these assays are still in clin-
ical use (Jordan et al., 2002; Preiser et al., 2003; Weinberg et al., 2000), the availability
of more automated quantitative PCR systems has changed HCMV diagnostics.
The most widely used semi-automated commercial method, Cobas Amplicor CMV
Monitor test (Roche Diagnostics), has simplified the laboratory practise significantly
compared with in-house quantitative tests, and also compared with pp65 antigenemia
assay (Boivin et al., 2000; Caliendo et al., 2000; Humar et al., 1999; Rollag et al., 2002;
Sia et al., 2000a; Tong et al., 2000). The development of real-time methodology and the
availability of automated real-time instruments, have further simplified quantitative PCR
assays and reduced the turnaround time needed for the test performance. In recent years,
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many applications usually based on TaqMan or LightCycler technologies, have been de-
scribed for the measurement of HCMV DNA in the blood samples of transplant patients
(Gault et al., 2001; Kearns et al., 2001; Pang et al., 2003; Sanchez and Storch, 2002;
Schaade et al., 2000).
Many technical factors may induce variability between different quantitave PCR assays,
including nucleic acid extraction method, amplification instrument, quantitation stand-
ard, or detection method. Furthermore, it has been suggested that the sensitivity of the
quantitative assay may be dependent on the target sequence and the selected oligonucle-
otides (Mendez et al., 1998b). The polymerase gene (UL54) is the target region in com-
mercially available Cobas Amplicor CMV Monitor assay (Roche Diagnostics). In addi-
tion to this, many different target sequences and oligonucleotides have successfully been
used in in-house quantitative assays, including gB (UL55), IE (UL122/123), pp65
(UL83), US17 gene and HindIII-X fragment (Gault et al., 2001; Guiver et al., 2001;
Ikewaki et al., 2003; Li et al., 2003; Mendez et al., 1998b; Mengelle et al., 2003a; Pang
et al., 2003; Stocher and Berg, 2002). So far, the most appropriate region for amplifica-
tion of HCMV DNA has not been established. In addition, one of most important is-
sues which may cause variability in the results of different tests is the choice of specimen
type.
The measurement of viral load has successfully been used also in the diagnostics of HCMV
in the transplant patients. Both commercially available and in-house quantitative HCMV
DNA assays are currently used in clinical laboratories. Quantitative PCR tests can be used
for the distinction of symptomatic and asymptomatic HCMV infection (Caliendo et al.,
2002; Caliendo et al., 2000; Razonable et al., 2002b). In recent years, quantitative PCR
tests have also been used in the guiding of pre-emptive therapy (Daly et al., 2002; Paya
et al., 2002), though the optimal threshold of viral load which predicts the likelihood of
HCMV disease, has not yet been defined. In any case, it is generally accepted that high-
er HCMV DNA load predicts clinical progression to HCMV disease (Razonable et al.,
2002b). Recently, quantitative PCR has also proven its utility in the monitoring of re-
sponse to antiviral treatment (Hadaya et al., 2003; Jordan et al., 2002; Pang et al., 2003).
The persistence of HCMV DNA at the end of therapy has been demonstrated to be a
risk factor for a recurrence (Jordan et al., 2002; Razonable et al., 2002a; Sia et al., 2000b;
Weinberg et al., 2000). In addition to testing viral load, applications of viral load kinet-
ics (i.e., rate of change of viral load) have been found to be a useful early predictor of
patients at risk for developing HCMV disease, and also to predict recurrence (Emery et
al., 2000b; Humar et al., 2002a). Viral load kinetics have also been reported to serve as
an early indicator of viral resistance (Emery and Griffiths, 2000).
3.5.6. Other nucleic acid amplification methods
It has been suggested that the detection of HCMV mRNA would correlate better with
symptomatic HCMV infection than DNA, because of the ability of the virus to remain
latent in the host cell. Previously, in-house RT-PCR methods were used for the detec-
tion of mainly immediate early or late transcripts in blood samples of transplant patients
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(Bitsch et al., 1993; Gaeta et al., 1997; Nelson et al., 1996; Randhawa et al., 1994). The
sensitivities, specificities and correlations with HCMV disease of these tests varied con-
siderably. Later, many applications based on NASBA technique have been employed.
NASBA is an isothermal amplification process which involves the coordinated activities
of three different enzymes: ribonuclease H, reverse transcriptase and DNA-dependent
RNA polymerase (Compton, 1991). The final product of the process is a specific single-
stranded RNA, instead of the dsDNA of PCR. The high sensitivity in detecting HCMV
infection has been shown by the NASBA assay with the IE-1 target (Blok et al., 1999;
Blok et al., 2000; Goossens et al., 1999; Oldenburg et al., 2000). In recent years, many
applications of the NASBA technique based on the detection of pp67 mRNA have been
developed and the test application is also commercially available (Blok et al., 2000; Ger-
na et al., 2003; Gerna et al., 1999; Merlino et al., 2002; Witt et al., 2000). These assays
detect pp67 mRNA, which is transcribed late in the viral replicative cycle, in a qualita-
tive manner. pp67 NASBA assay may have a clinical utility in both early diagnosis of
symptomatic HCMV infection and monitoring transplant patients with active disease,
as well as in guiding pre-emptive therapy (Caliendo et al., 2002; Gerna et al., 2003; Witt
et al., 2000). Recently, the pp67 NASBA has also been combined with the quantitative
detection of IE-1 mRNA, which may improve the clinical utility of this technique (Gre-
ijer et al., 2002).
HCMV DNA has also been detected by a signal amplification method, Hybrid Capture
System, from blood samples of transplant patients (Aitken et al., 1999; Bhorade et al.,
2001; Ho et al., 2000; Mazzulli et al., 1999; Norris et al., 2002). The Hybrid Capture
System is a solution hybridization assay that involves amplified detection instead of am-
plification of the desired nucleic acid fragment. The assay uses a specific RNA probe which
targets 17 % of the HCMV genome. The RNA-DNA hybrid is captured by a monoclonal
antibody and is detected by a luminometer. Both qualitative and quantitative applica-
tions are commercially available. The quantitative form has clinical utility in the diag-
nosis and monitoring of HCMV infection (Aitken et al., 1999; Bhorade et al., 2001; Ho
et al., 2000; Norris et al., 2002).
3.6. Antiviral susceptibility testing
After the more widespread use of antiviral drugs, resistant HCMV strains havebeen re-
ported also in the transplant patient population (Isada et al., 2002; Limaye, 2002; Limaye
et al., 2002; Lurain et al., 2002). The methods used for antiviral susceptibility testing can
be divided into phenotypic and genotypic assays (Erice, 1999). Phenotypic assays rely on
the suppression of viral growth in the presence of antiviral agents. Various modifications
have been employed (Erice, 1999; Landry et al., 2000; McSharry et al., 1998), of which
the plaque reduction assay is considered as a standard method. A major limiting factor
of the phenotypic methods, is that they require viral culture from the clinical sample,
followed by several passages to reach the necessary viral titres for the performance of the
assay, which can take up 4-6 weeks. Because the assay is burdensome and it lacks stand-
ardization, it is not routinely undertaken in the majority of centers.
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The fact, that specific mutations in the UL97 and UL54 genes are associated with anti-
viral drug resistance, have led to the development of genetic methods. These are based
on PCR amplification of the specific region of the genome followed by restriction en-
zyme analysis or direct sequencing of the amplification product/products (Alain et al.,
1997; Lurain et al., 2002; Mendez et al., 1999b; Wolf et al., 1995). An obvious advan-
tage of these assays is the possibility to use clinical specimens directly, rather than virus
isolates, which significantly shortens the time required for performance of the test. In
addition, mixtures of the different strains are not always detected in viral culture meth-
ods (Lurain et al., 2002). However, standardization and validation of these methods are
needed for clinical use.
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Aims of the study
The aims of the present study were:
To evaluate the value of quantitative PCR in the diagnosis of HCMV infection in organ
transplant patients (I)
To evaluate the clinical utility of quantitative PCR in the monitoring of active HCMV
infection and in the monitoring of the response to antiviral treatment in individual liver
and kidney transplant patients (II, III)
To develop a faster and more high-throughput quantitative PCR method for the deter-
mination of HCMV DNA viral loads in the peripheral blood of organ transplant patients
and to evaluate its value in the diagnosis and monitoring of HCMV infection in trans-
plant patients (IV).
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Materials and methods
1. Clinical specimens
The clinical material consisted of consecutive EDTA-blood samples from adult liver and
kidney transplant patients sent to the Department of Virology, Helsinki University Central
Hospital. The number of specimens analysed were 253, 243, 342 and 270 in the studies
I, II, III and IV, respectively. The more detailed descriptions of each patient population
are found in the Results and Discussion.
2. Shell vial culture assay (III)
A modification of the rapid shell vial culture (Gleaves et al., 1984) was used for the iso-
lation of HCMV in blood specimens, as described previously (Lautenschlager et al., 1989).
Indirect immunofluorescence against the HCMV immediate early antigen (BioSoft,
Varilhes, France) was used for the detection of HCMV positive cells in the fibroblast
cultures.
3. pp65 antigenemia assay (I, II, III, IV)
The standard HCMV pp65 antigenemia test was used for the detection of HCMV viral
proteins in the leukocytes, as described previously (Koskinen et al., 1993b; The et al.,
1990; van den Berg et al., 1989). In short, the leukocytes were isolated from blood sam-
ples and cytocentrifuged onto microscope slides, which were dried and fixed in cold ac-
etone. Immunoperoxidase staining and a monoclonal antibody against HCMV pp65
antigen (Biotest, Frankfurt, Germany) were used for the demonstration of viral proteins
in cells. The positive results were quantified by counting the number of pp65-positive
cells per 50 000 leukocytes on the slide.
4. Quantitative HCMV PCR test (I, II, III, IV)
As a commercial quantitative PCR assay, the Cobas Amplicor CMV Monitor test (Ro-
che Diagnostics) was used for the quantitation of HCMV DNA in plasma samples. Plas-
ma was isolated by centrifugation from the EDTA-blood specimens within 24 h after
collection. The test was run according to the manufacturer’s instructions. Briefly, a known
number of the plasmid quantitation standard, with the same primer binding sites as the
HCMV target, was added to each sample before DNA extraction. DNA isolation from
200 µl of plasma was performed by lysis of virus particles followed by alcohol precipita-
tion. PCR amplification was performed using a biotinylated primer pair, selected from
the amino terminus of the DNA polymerase gene, spanning the 365 bp fragment. The
PCR products of HCMV and quantitation standard were denatured and serially diluted
to achieve a larger dynamic range for quantitation. Specific probes, on the basis of the
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unique probe binding sites for both HCMV and quantitation standard, were used in
hybridization of HCMV and quantitation standard PCR products. Target-probe com-
plexes were detected spectrophotometrically using avidin-horseradish peroxidase conju-
gate and its substrates, and the levels of HCMV DNA in the test samples were calculat-
ed by comparing the HCMV signal to the quantitation standard signal. The linear range
of the assay was 400-100 000 copies/ml (cps/ml) according to the manufacturer’s recom-
mendations.
5. Real-time HCMV PCR test (IV)
In the present study, the quantitative real-time HCMV PCR test based on TaqMan tech-
nology was developed. The assay was used for the quantitation of HCMV DNA in plas-
ma samples.
5.1. DNA extraction
DNA was extracted from the plasma samples by the automated MagNA Pure LC instru-
ment (Roche Diagnostics), which uses magnetic bead technology, and the MagNA Pure
LC Total Nucleic Acid Kit (Roche Diagnostics). DNA extraction was performed from
200 µl of plasma according to the manufacturer’s instructions. Briefly, the samples were
dissolved and stabilized by proteinase K incubation and by lysis buffer containing dena-
turising agents. The released nucleic acids were bound to the silica-coated magnetic par-
ticles. After several washing steps, the purified nucleic acids were eluted in 50 µl of low
salt elution buffer. Ten µl of the eluted nucleic acid solution was further used for each
real-time reaction.
5.2. Standards
Plasmid pCMV1 was prepared to achieve a quantitative standard curve for a real-time
PCR. The 421 bp fragment, which consisted of the region amplified in real-time assay,
from the pp65 gene (GenBank accession number M15120), was amplified using prim-
ers p1 and p2 (Table 1). The product was subsequently cloned into the pGEM-T vector
(Promega), and after the purification the plasmid was linearized. The concentration of
the plasmid was measured by spectrophotometry and the amount of DNA was calculat-
ed corresponding to copies of DNA. The plasmid was diluted to obtain the 10-fold se-
ries from 10 to 106 copies per reaction to create a standard curve.
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5.3. Amplification
The primers 1 and 2, and the probe (Table 1), were selected from the pp65 gene (Gen-
Bank accession number M15120) using the PrimerExpress software program (Applied
Biosystems). The length of the amplified product was 57 bp. The amplifications were
carried out in the ABI PRISM 7900HT sequence detector instrument (Applied Biosys-
tems) in a final volume of 50 µl. The PCR mixture contained 300 nM of primer 1, 900
nM of primer 2, 250 nM of probe and 1 x TaqMan universal mix (Applied Biosystems).
In the reaction, dUTP was used instead of dTTP. An aliquot of 10 µl template was add-
ed to each reaction and all samples were run in duplicates. The first step of the amplifi-
cation program was 2 min at 50°C, which allowed uracil-N-glycosylase (included in the
TaqMan Universal mix) to destroy possible contaminating pre-amplified PCR products
containing dUTP. In incubation of 10 min at 95°C, AmpliTaq Gold enzyme was allowed
to activate and nucleic acids were allowed to denature. Forty-five cycles of denaturation
at 95°C for 15 s and of annealing-extension at 60°C for 1 min were carried out for the
amplification of HCMV DNA.
6. Statistical analysis
Quantitative results of pp65 antigenemia and quantitative PCR assays were expressed as
means ± SD (I) or as medians (II, III, IV). Student’s t-test (I) or Mann-Whitney U-test
(II, III, IV), and Pearson correlation and linear regression (IV) were used for the statisti-
cal analysis of the quantitative results, and P-values <0.05 were considered statistically
significant.
Table 1. Primers and probe used in real-time HCMV PCR.
Primer or probe Sequence (5´-3´)a
p1 CGA CGA CGA CGT CTG GAC CAG
p2 CTG CCA TAC GCC TTC CAA TTC G
1 TCG CGC CCG AAG AGG
2 CGC CCG GAT TGT GGA TT
probe FAM-CAC CGA CGA CGA TTC CGA CAA CG-TAMRA
aModiﬁcations: FAM, 6-carboxy-f luorescein; TAMRA, 6-carboxy-tetramethyl-rhodamine
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Results and discussion
1. Comparison of quantitative PCR assay,
Cobas Amplicor CMV Monitor test, and pp65
antigenemia assay (I)
In our preliminary work (I), the suitability of the commercially available quantitative PCR
test, Cobas Amplicor CMV Monitor test (Roche Diagnostics), was evaluated for the
detection of HCMV DNA in plasma samples of transplant patients by comparing the
results of PCR with those determined by pp65 antigenemia assay. Totally 253 consecu-
tive blood samples both from adult liver and kidney patients were investigated by both
methods in parallel from the concurrently obtained samples.
1.1. Sensitivities of the assays
The results of individual samples by the quantitative tests were treated in a qualitative
manner for the assessment of sensitivity and specificity of the Cobas Monitor assay. A
sample was considered positive if HCMV DNA was detected at any measured level by
Cobas test, and if ≥1 positive cell(s) were demonstrated by pp65 antigenemia test.
HCMV positivity by either one or both of the quantitative methods used were detected
in 35 % (89/253) of the samples investigated (Table 2.). 164 samples were negative by
both tests. The PCR assay found 88 % (78/89) (range 274-165000 cps/ml) and the pp65
test 89 % (79/89) (range 1-1500 positive cells) of the positive findings, respectively. Eleven
out of 89 PCR negative/pp65 positive samples were found. All of these samples had low-
level antigenemia, 1-5 positive cells in pp65 test. On the other hand, 10 PCR positive/
pp65 negative samples were detected. Six of these samples were obtained during GCV
treatment and four of these before antigenemia appeared. The greatest amount of PCR
positive/pp65 negative samples had a low-level DNAemia. Very similar findings have been
reported also by other groups evaluating the Cobas CMV Monitor assay (Caliendo et al.,
2000; Flexman et al., 2001; Humar et al., 1999; Razonable et al., 2001a). However, the
commercial quantitative plasma Cobas Monitor PCR test detected all the HCMV infec-
tions which required specific antiviral treatment corresponding to the previously report-
ed cut-off level of 10 positive cells/50 000 leukocytes in pp65 antigenemia test (The et
al., 1990; van den Berg et al., 1989).
Table 2. Comparison of the qualitative results of the Cobas Monitor and pp65-
antigenemia assays.
pp65 positive pp65 negative Total
Cobas positive 68 10 78
Cobas negative 11 164 175
Total 79 174 253
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1.2. Correlation of quantitative PCR assay and pp65
antigenemia test
The good correlation between the quantitative results of individual blood samples meas-
ured by pp65 antigenemia assay and by Cobas Monitor assay was shown (I: Fig. 1). The
samples were divided into four different groups on the basis of the results of the pp65
antigenemia test (<10, 10-<100, 100 -<1000 and 1000-<10000 positive cells /50 000
leukocytes). The HCMV DNA levels obtained by the Cobas Monitor assay in the dif-
ferent groups were 3137±5158 cps/ml, 20 372±43 496 cps/ml, 37 920±32 300 cps/ml
and 100450±28 179 cps/ml, respectively. The differences were statistically significant be-
tween the groups <10 and 10-<100, as well as 100-<1000 and 1000-<10 000.
We also studied the viral load values prior to and at the time of GCV administration by
the Cobas Monitor test. The DNA levels before the treatment varied between 392 and
3440 cps/ml, except in one patient with 16 500 cps/ml. On the other hand, those pa-
tients who received antiviral treatment due to symptomatic infection, demonstrated higher
plasma DNA levels (1420-103 000 cps/ml) when treatment was started. Previously it had
been reported that also higher levels of antigenemia correlate with symptomatic HCMV
infection (Boeckh and Boivin, 1998; van den Berg et al., 1989). Our PCR findings were
quite similar to those of a previously published study, in which the Cobas Monitor assay
and pp65 antigenemia test were used (Humar et al., 1999). The mean peak viral load at
the time of HCMV diagnosis was significantly higher than that of the patients with
asymptomatic infection as measured by the Cobas assay (73 715 cps/ml vs 3615 cps/ml)
(Humar et al., 1999). Elevated antigenemia levels in patients with symptomatic infec-
tion were also observed in that study. Higher HCMV DNA levels in the leukocyte frac-
tion from patients with symptomatic infection than of those with asymptomatic infec-
tion, assessed by different quantitative nucleic acid-based methods, have also been shown
recently (Aitken et al., 1999; Mendez et al., 1998a; Roberts et al., 1998).
The follow-up curves of two liver transplant patients were shown (I: Fig. 2). The strong
temporal relationship between antigenemia and DNAemia was observed in both patients.
The high antigenemia level (100 positive cells) correlated with the clinical symptoms as
well as with the results of quantitative PCR (25 100 cps/ml) in one patient, who needed
antiviral treatment (GCV) due to symptomatic HCMV infection (I: Fig. 2a). The pa-
tient (I: Fig. 2b) with no clinical symptoms and without antiviral treatment, showed only
moderate level DNAemia (4330 cps/ml) at the time of low antigenemia peak (5 positive
cells). In both cases, the DNAemia, and also antigenemia, disappeared during the fol-
low-up period.
Our results are in agreement with those reported by other studies supporting clinical use
of the Cobas CMV Monitor assay (Caliendo et al., 2000; Humar et al., 1999). In these
studies, a good correlation between the Cobas Monitor test and the pp65 antigenemia
assay has been shown. On the basis of that, and due to our own encouraging results, it
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was supposed that the quantitative Cobas Monitor assay may be used in the detection of
HCMV infection, and also in the monitoring of HCMV infection and of the response
to the antiviral treatment in individual patients, in a similar way as with the pp65 anti-
genemia assay.
1.3. Cobas Amplicor CMV Monitor test
Despite the fact that the Cobas Monitor PCR test measures plasma DNA while the an-
tigenemia assay measures pp65 antigen positivity in leukocytes, both quantitative meth-
ods were shown to be equally useful in the diagnosis of clinically significant HCMV.
However, the quantitative Cobas Monitor assay had several advantages over the pp65
antigenemia test. It was more automated, including the manual nucleic acid extraction
step followed by the automated amplification and detection steps. The hands-on time
needed for performance of the test decreased significantly when using the semi-automated
Cobas Monitor system. In addition, the Cobas Monitor assay used only 200 µl plasma
instead of the 3-5 ml of whole blood required for the antigenemia test. The processing
and handling of plasma samples were easier compared with the leukocyte preparation
required for the pp65 test. The use of quantitative semi-automated PCR assay allowed
larger amounts of samples to be investigated within a shorter time, and also by a more
convenient manner.
Although there have been attempts to standardize the pp65 antigenemia method (Ger-
na et al., 1998; The et al., 1995), various modifications of the test are in clinical use. Major
advantages of the introduction of the commercial Cobas CMV Monitor test was that it
offered a standardized method and introduced comparability between centers. Although
in-house quantitative PCR assays for the quantitation of HCMV DNA in blood sam-
ples have also been developed and used in clinical studies (Barber et al., 1999; Boom et
al., 1999; Cope et al., 1997; Mendez et al., 1998a; Toyoda et al., 1997), these tests have
not been well standardized either. These tests may differ in many factors, such as target
sequences, oligonucleotides, nucleic acid extraction methods and instruments used for
amplification, which may cause differences in the performance of the test, detection limits,
sensitivity and linear range. As a result, high variability between viral load values of dif-
ferent in-house quantitative assays and Cobas Monitor test have been reported (Calien-
do et al., 2001; Razonable et al., 2001a). This has made comparison of quantitative re-
sults between centers difficult.
2. Diagnostic validation and use of the Cobas
Amplicor CMV Monitor assay (II, III)
Although quantitative PCR assays were already widely used in HCMV diagnostics, the
clinical correlation of the findings was not as clear as that with the pp65 antigenemia test.
The antigenemia test has been the most commonly used method for 15 years in the de-
tection of HCMV infection, and also for the assessment of viral load and the monitor-
ing of response to antiviral treatment (Boeckh and Boivin, 1998; Gerna et al., 1998; Sia
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and Patel, 2000; The et al., 1990; van den Berg et al., 1989). In the present study, the
clinical utility of the Cobas Amplicor CMV Monitor assay was further evaluated in par-
allel with pp65 antigenemia test in liver (II) and kidney (III) transplant patient groups,
not only in the diagnosis of HCMV infection but also in the monitoring of individual
patients during HCMV infection and antiviral treatment.
2.1. Comparison of the quantitative assays and shell vial
culture assay (III)
The comparison of the qualitative results of 342 consecutive blood samples of kidney
transplant patients (III) between the Cobas Monitor and the pp65 antigenemia assays,
were performed in a similar way as in our previous work (I).
The sensitivities of 78 % by Cobas Monitor test and 88 % by pp65 antigenemia assay,
respectively, were observed in the detection of HCMV positive findings. Instead, shell
vial culture assay was far less sensitive (38 %) for the detection of the virus in blood than
the other two methods, as reported previously (Evans et al., 1999; Wirgart et al., 1996).
Only small differences similar to those of our previous work (I) between Cobas Monitor
test and pp65 antigenemia assay were observed. In general, the Cobas Monitor test de-
tected all of the infections which needed antiviral treatment (>16 positive cells in pp65
test). On the other hand the shell vial culture assay remained negative through the fol-
low-up period even in a case with a symptomatic infection.
2.2. Diagnosis of symptomatic HCMV infection by the
Cobas Amplicor CMV Monitor assay (II, III)
In our preliminary work (I), we already showed the correlations between the viral loads
in DNA and pp65 levels after transplantation and at the time when specific antiviral treat-
ment was started. In studies II and III, the peak viral load values were assessed in the
patients with symptomatic HCMV infection and in the patients with asymptomatic in-
fection, using the Cobas Amplicor CMV Monitor test and the pp65 antigenemia test.
In the liver patient group (II), altogether 243 consecutive blood samples from 27 patients
were investigated. DNAemia and antigenemia were detected in 20 patients. In addition,
a very low antigenemia level (3 positive cells) was observed in one more patient 76 days
after transplantation. The subsequent samples, however, were all negative. On the basis
of this, the patient was classified into the HCMV negative group. Thirteen out of 20 PCR
positive/pp65 positive patients developed symptomatic HCMV infection 27 to 52 days
after transplantation and 7 patients remained asymptomatic. All symptomatic patients
were treated with i.v. GCV. In the kidney patient group (III), altogether 342 blood sam-
ples were investigated. Thirty-one out of 116 patients had at least one positive finding
by PCR or pp65 test or by both tests. Fourteen out of these patients developed sympto-
matic infection and were treated with i.v. GCV.
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The peak viral loads observed in the patient groups II and III measured by Cobas Mon-
itor test and by pp65 antigenemia are shown in Figure 4. In both patients groups, the
median peak viral load values of the patients with symptomatic infection were statisti-
cally higher than those of the patients without symptomatic infection by both quantita-
tive tests. These results are in agreement with other groups evaluating Cobas Monitor assay
(Caliendo et al., 2002; Caliendo et al., 2000; Flexman et al., 2001; Humar et al., 1999).
Very similar results had also been shown by in-house quantitative PCR methods, and other
commercial quantitative methods or modifications, using either plasma samples or leu-
kocytes (Aitken et al., 1999; Ferreira-Gonzalez et al., 1999; Mendez et al., 1998a; Rob-
erts et al., 1998; Weinberg et al., 2000).
2.3. Monitoring of HCMV infection in individual patients (II, III)
The liver transplant patients (II) were frequently monitored during the first three months
after transplantation. The response to the antiviral treatment was monitored in the symp-
tomatic patient group and, in the case of asymptomatic infection, the patient was mon-
itored until pp65 antigenemia disappeared. Five of the 13 symptomatic infections were
found from patients with primary infections (D+/R-), usually with high peak viral loads
measured by both methods (in four cases >10 000 cps/ml and ≥50 positive cells and in
one case 526 cps/ml and 80 positive cells) (II: Fig. 2). Six patients with symptomatic
infection had reactivations/reinfections (II: Fig. 3). The peak viral loads in this D+/R+
group, as assessed by the Cobas Monitor test, were high (>10 000 cps/ml) in three cases,
and lower (range 2290-7730 cps/ml) in the other three cases. The peak viral loads as
determined by pp65 assay were high (≥50 positive cells) in all of these cases. One patient
in the D-/R+ group who had symptomatic reactivation/reinfection, had moderate peak
viral load by the Cobas Monitor test (6510 cps/ml and 100 positive cells), and another
one had lower peak values by both methods (1120 cps/ml and 25 positive cells) (II: Fig.
4). All liver recipients with asymptomatic HCMV infection belonged to the serostatus
group of D+/R+ (reactivations/reinfections) (II: Fig. 5), and were not treated with anti-
virals. The overall peak viral loads of the asymptomatic patient group were significantly
lower than those of symptomatic infections. In this study, there were PCR negative pa-
tients in each serostatus groups: D+/R- (n = 1), D+/R+ (n = 2), D-/R+ (n = 3), and D-/
R- (n =1). Table 3 shows the peak viral load values demonstrated by the Cobas Monitor
and pp65 assays in each serostatus group.
Table 3. Peak viral loads demonstrated by the Cobas Monitor and pp65
antigenemia assays in the different serostatus groups.
No. of Cobas peak range, pp65 peak range,
Serostatus Patients cps/ml (median) pos cells/50 000 leukocytes
(median)
D+/R- (symptomatic) 5 526-21 600 (16 100) 50-800 (100)
D+/R+ (symptomatic) 6 2520-126 000 (8965) 50-300 (185)
D-/R+ (symptomatic) 2 1120-6510 (3815) 25-100 (62)
D+/R+ (asymptomatic) 7 915-5490 (2240) 15-60 (29)
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In the liver patient group (II), the high peak viral loads (>10 000 cps/ml) were seen es-
pecially in the D+/R- group with primary HCMV infections. In addition, the median
peak viral load of the symptomatic infections were significantly higher than those of the
symptomatic infections (10 200 cps/ml versus 2240 cps/ml). Instead, the peak viral loads
of the asymptomatic D+/R+ patients did not exceed 5500 cps/ml, and only two of these
patients had viral loads over 5000 cps/ml. Thus, it was supposed that the cut-off level of
2000-5000 cps/ml might be optimal for predicting HCMV disease in seropositive recip-
ients, at least in this transplant patient group, as was proposed also by other groups us-
ing the Cobas Monitor test (Caliendo et al., 2002; Humar et al., 1999).
The kidney transplant patients (III) were monitored weekly to follow the response to
antiviral treatment and, in the case of asymptomatic infection, until the pp65 antigene-
mia subsided. Five of the symptomatic cases belonged to the D+/R- group, one case to
the R-/D- group, seven cases to the D+/R+ group and one case to the D-/R+ group, re-
spectively. All asymptomatic patients had reactivations or reinfections being seropositive
before transplantation (D+/R+ or D-/R+). In this patient group, we did not observe sig-
nificantly higher peak viral loads in the patients with primary infections than in the re-
activation/reinfection groups. However, the overall peak viral loads were significantly
higher in the symptomatic patients than in the asymptomatic patients as was the case with
the liver transplant patient group (II) (Figure 4.). Therefore, a similar cut-off level may
be considered appropriate for predicting HCMV disease also in this patient group.
Figure 4. Median values of peak viral loads of symptomatic and asymtomatic
HCMV infections assessed by PCR test and by pp65 antigenemia assay.
A and B in liver patient group (II), C and D in kidney patient group (III).
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In both patient groups, time-related viral load values assessed by the Cobas Monitor test
and pp65 assay correlated well in symptomatic and asymptomatic infections (as shown
in more detail in the original publications, II: Fig. 2, 3, 4 and 5; III: Fig. 2). The response
to the antiviral treatment was easy to follow by both methods. This indicated the suita-
bility of the Cobas Monitor assay, not only for the diagnosis of symptomatic HCMV
infection, but also for the monitoring of individual liver and kidney transplant patients.
3. HCMV real-time PCR assay (IV)
The real-time PCR assay was developed in the present study because the need for a fast-
er and more automated assay with greater capacity for the quantitation of HCMV viral
load in plasma samples was obvious. The real-time technology based on TaqMan chem-
istry and the MagNA Pure LC nucleic acid extraction system (Roche Diagnostics) were
selected for allowing the improvements. The nucleotide sequence region for amplifica-
tion was chosen from the pp65 gene (UL83) of HCMV, instead of the DNA polymer-
ase region used in the Cobas Amplicor CMV Monitor assay. The primers and probe used
are described in the Materials and Methods.
3.1. Technical characteristics of HCMV real-time assay
3.1.1. Detection limit, linearity and reproducibility of
HCMV real-time assay
In the developed assay 10 plasmid copies per reaction were reproducibly detected, and
the 250 HCMV cps/ml plasma was assessed as the detection limit of the test. A broad
linear range, from 250 up to 25 000 000 cps/ml plasma, was observed. This was much
broader than that of the Cobas Monitor assay (from 400 to 100 000 cps/ml plasma). Good
amplification efficiency of the standard plasmid was indicated by the correlation efficient
values of at least 0.9930 and the slope values between –3.3 and –3.4 within different PCR
runs, when the 10-fold dilution series of the standard plasmid was used.
The reproducibility of the TaqMan test was assessed using the clinical plasma specimens,
in which the HCMV copy number varied, as specified by the Cobas Monitor assay, rep-
resenting the whole linear range of the real-time test. Four different samples were used
for both intra-assay and inter-assay analyses. The samples were investigated as triplicates
for intra-assay analysis, and in three different test runs for inter-assay analysis. The coef-
ficient of variations (%) ranged from 5.12 % to 13.1 % in intra-assay analysis and from
4.50 % to 19.6 % in inter-assay analysis, being the highest in the low-copy samples. The
results were comparable with those of other groups employing real-time HCMV tests
(Gault et al., 2001; Machida et al., 2000; Sanchez and Storch, 2002) indicating a good
accuracy of the real-time PCR.
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3.1.2. Automated extraction of nucleic acids
Turnaround time of a clinical PCR test depends widely on the method used for nucleic
acid extraction. Conventional extraction with an organic solution, such as phenol, is ef-
ficient but it is also very laborious and time-consuming, and therefore it is not suitable
for the processing of a large number of samples. Commercial nucleic acid isolation kits
have been developed to reduce time and they have also been widely used in the quanti-
tative HCMV PCR assays described (Gault et al., 2001; Mendez et al., 1998a; Michaelides
et al., 2003; Pang et al., 2003; Razonable et al., 2002a). Also the commercially available
Cobas Amplicor CMV Monitor test has been assessed to use manual nucleic acid extrac-
tion (Roche Diagnostics). However, also these kits usually need long hands-on time and
are usually not suitable for automation. In this study, we described the use of an auto-
mated nucleic acid extraction device, MagNA Pure LC (Roche Diagnostics), and the Total
Nucleic Acid Isolation Kit (Roche Diagnostics) for the processing of plasma specimens.
In this purification system released nucleic acids are bound to the silica-coated magnetic
particles, washed and then eluted. Technically the most important advantage of the
MagNA Pure instrument was the short hands-on time needed for preparing samples,
about 15 minutes for the set-up of the instrument. Thirty-two samples could be proc-
essed within 1.5 hours, which greatly increased the capacity of the test. In recent years,
automated nucleic acid extraction instruments have been combined with HCMV real-
time assays also by other groups (Geddes et al., 2003; Mengelle et al., 2003b).
Good performance of a diagnostic PCR test with purified nucleic acid is also dependent
on the method of nucleic acid extraction. Many potential inhibitory compounds derived
from the clinical samples have been reported (Wilson, 1997), including also components
of blood, such as hemoglobin, heme and IgG antibody (Akane et al., 1994; Al-Soud et
al., 2000; Al-Soud and Radstrom, 2001), or added anticoagulants such as heparin (Sat-
sangi et al., 1994). In recent years, the MagNA Pure LC instrument has been proven to
be an efficient nucleic acid extraction system in various sample types (Espy et al., 2001;
Kessler et al., 2001; Rabenau et al., 2002). In our hands, the MagNA Pure instrument
was proven to present an efficient method for the processing of clinical plasma specimens.
In our evaluation study of 160 plasma samples, the results after the conventional phenol
extraction and after the MagNA Pure system were comparable with each other, indicat-
ing a good efficiency of the automated extraction system. Recently, MagNA Pure LC was
shown to provide an efficient and reproducible DNA purification method in the other
real-time HCMV test that analysed clinical plasma specimens (Stocher and Berg, 2002).
3.1.3. Turnaround time of HCMV real-time assay
In addition to the development of automated nucleic extraction devices, the introduc-
tion of real-time technology has been an important element for improvements of diag-
nostic quantitative PCR assays. The use of real-time technology has reduced the entire
time needed for PCR significantly when compared with PCR using conventional instru-
ments, and also when compared with commercially available kits using competitive quan-
titative PCR, in which amplification and detection follow each other. Modern real-time
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instruments allow amplification, detection of PCR products and quantitation of the vi-
ral DNA to occur simultaneously and quickly. In our work, the use of the ABI PRISM
7900HT Sequence Detector instrument (Applied Biosystems) and TaqMan technology
reduced the entire testing time significantly when compared with Cobas Monitor test,
being 3-4 hours instead of 7-8 hours, depending on the number of samples analysed.
3.2. Diagnostic validation and use of
HCMV real-time PCR assay
The clinical utility of the developed HCMV real-time assay in the detection and moni-
toring of HCMV infection was evaluated by investigating 270 consecutive blood sam-
ples from 23 adult liver and four kidney recipients. The results were compared with those
of Cobas Amplicor CMV Monitor assay, and also with those of the pp65 antigenemia
assay. In the qualitative comparisons, ≥250 cps/ml and ≥400 cps/ml, the detection lim-
its of the quantitative PCRs, were considered HCMV DNA positive for real-time and
Cobas Monitor assays, respectively. In the pp65 antigenemia assay ≥1 positive cell(s) in
an individual sample was considered positive.
3.2.1. Detection of HCMV DNA by real-time assay
The sensitivities of each method in the different patient populations (in studies I, III and
IV) in the detection of HCMV in blood samples are summarised in Table 4.
The developed HCMV real-time PCR assay was found to be the most sensitive assay in
this patient population (IV), detecting 92 % of the positive findings. Instead, the Cobas
Monitor test was less sensitive than the pp65 antigenemia assay in this study, as well as
in our study III, and as sensitive as pp65 in our study I. Recently, the better sensitivities
of the quantitative plasma PCR tests compared with the pp65 antigenemia assay have
also been reported by other groups using real time PCR (Pang et al., 2003; Tanaka et al.,
2002) or modified Cobas Monitor assay (Hadaya et al., 2003). In all of these reports the
detection limit of PCR assay has been lower than that of Cobas test (400 cps/ml). The
equivalent of the sample volume added to each amplification reaction is one of the most
important factors which can affect the sensitivity of the test. In our work the sample equiv-
alent in the real-time assay was larger than in the Cobas Monitor test (40 µl in real-time
versus 25 µl in Cobas). The detection limits of the described plasma real-time HCMV
assays are usually lower than that of the Cobas Monitor assay (Leruez-Ville et al., 2003;
Pang et al., 2003; Tanaka et al., 2002), which has increased the sensitivity of these tests
in the detection of HCMV DNA in blood samples.
Comparisons of the qualitative results of HCMV real-time, Cobas Monitor and pp65
assays in patient group IV are outlined in Table 5. The very similar findings as in our own
studies (I, III) and as previously reported studies by other groups (Caliendo et al., 2001;
Caliendo et al., 2000; Humar et al., 1999) concerning the differences between Cobas
Monitor test and pp65 antigenemia assay, were also shown in this patient group (IV).
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All 20 PCR negative/pp65 positive (PCR negative at least by one of the PCRs used) sam-
ples had low-level antigenemia, 1-5 positive cells. Many of these samples were detected
before the HCMV episode of the patient and the rise of DNAemia, or the samples were
obtained during GCV treatment. On the other hand, all 14 PCR positive/pp65 nega-
tive (PCR positive at least by one of the PCRs used) samples were obtained in the pa-
tients with GCV treatment. Most of these samples had a low-level DNAemia.
Also some inconsistency between the results of pp65 and PCR methods was observed.
Six out of 14 PCR positive/pp65 negative samples had a higher level of DNAemia by both
PCR assays (646-21 400 cps/ml by Cobas and 8015-73 530 cps/ml by real-time). All of
these samples were obtained during or soon after the antiviral treatment. Similar differ-
ences, the high HCMV DNA copies with non-detectable or very low antigenemia in some
samples, have also been observed by other groups (Gault et al., 2001; Griscelli et al., 2001;
Nazzari et al., 2000). The clinical significance of such findings is unclear.
In this study, the Cobas Monitor and real-time assays were compared also with each other.
Only small differences between these tests were observed when qualitative results were
evaluated, mainly because of different sensitivities of the assays. DNAemia was observed
in 15 samples only by real-time test, in which the levels of DNA were under or near the
detection limit of the Cobas test (303-861 cps/ml), except in one sample with 1637 cps/
ml. On the other hand, only one sample, obtained during antiviral treatment, was real-
time negative/Cobas positive (1930 cps/ml).
Table 4. The sensitivities of each detection method in different studies.
Detection method
Study No. Real-time PCR Cobas Monitor test pp65 assay
I - 88 % (78/79) 89 % (79/89)
III - 78 % (121/156) 88 % (138/156)
IV 92 % (106/115) 80 % (92/115) 88 % (101/115)
Table 5. Comparison of the qualitative results of the real-time, Cobas Monitor
and pp65- antigenemia assays.
Method
No of samples Real-time Cobas Monitor pp65-ag
81 + + +
10 + + -
11 + - +
4 + - -
1 - + +
0 - + -
8 - - +
155 - - -
Total 270 Total 106 pos. Total 92 pos. Total 101 pos.
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3.2.2. Correlation between quantitative tests
Good correlation between pp65 antigenemia and the Cobas Monitor assays (R = 0.80,
P < 0.0001), between pp65 and real-time assays (R = 0.84, P < 0.0001), and between
the Cobas Monitor and real-time assays (R = 0.64, P < 0.0001) was found (IV: Fig. 1).
The correlations were similar if the samples from liver and kidney transplant recipients
were evaluated separately. The lower correlation between the Cobas Monitor and real-
time assays may be due to one patient with an unusually prolonged antiviral treatment.
The value increased if this patient was not included (R = 0.71). Also the narrower linear
range of the Cobas Monitor assay could have had an effect on the lower correlation of
these two tests. The upper limit of the linear range of Cobas assay was guaranteed up to
100 000 cps/ml by the manufacturer, however, it has been reported to be lower (Calien-
do et al., 2001).
Different types of specimens, including peripheral whole blood and different blood com-
partments (plasma/serum, PBLs, PMNLs, PBMCs) have been used for the quantitation
of HCMV DNA in blood samples with varying results (Guiver et al., 2001; Hadaya et
al., 2003; Li et al., 2003; Mengelle et al., 2003a; Mengelle et al., 2003b; Razonable et
al., 2002a). Which is the most appropriate sample type for the measurement of viral load,
is still debated. In general, viral loads have been shown to be higher in whole blood or
leukocytes than in plasma (Gerna et al., 1994; Mengelle et al., 2003b; Razonable et al.,
2002a; Sia et al., 2000a). Thus, cell-containing specimens have been found to have a
higher sensitivity in the qualitative detection of HCMV compared with cell-free speci-
mens (plasma/serum) (Mengelle et al., 2003b; Razonable et al., 2002a). However, the
simultaneous high levels of DNA in the plasma and other blood compartments has been
shown during HCMV disease (Michaelides et al., 2003; Razonable et al., 2002a). A good
correlation between plasma and cell-containing samples, has also been reported in quan-
titative PCR (Michaelides et al., 2003; Razonable et al., 2001a; Sanchez and Storch,
2002). In addition, quantitative PCR assays with low detection limits have been devel-
oped for the detection of HCMV DNA in plasma samples (Hadaya et al., 2003; Pang et
al., 2003), and also a good correlation between these tests and pp65 antigenemia test has
been shown. These results are in agreement with ours indicating the suitability of plas-
ma samples for the measurement of viral loads in blood. Easy handling of plasma sam-
ples is an advantage in the laboratory. Delayed separation of plasma has been reported
to increase the frequency of DNA positivity for HCMV probably due to latently infect-
ed leukocytes (Schafer et al., 2000). However, a recent report indicated that a 24-hour
delay in plasma isolation did not affect viral quantitation by real-time PCR (Nesbitt et
al., 2004). In addition, the test is not dependent on the number of leukocytes, and thus
it may also be used in patients with leukopenia because of immunosuppressive therapy
or during GCV treatment.
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3.2.3. Diagnosis and monitoring of HCMV infection in individual
patients by HCMV real-time assay
All liver transplant patients were frequently monitored. The liver patients with sympto-
matic infections were treated with i.v. GCV and were monitored until pp65 antigene-
mia and DNAemia subsided. All kidney recipients had symptoms already before the first
sample was obtained, and were also frequently monitored for response to the antiviral
treatment in a similar way to the liver recipients. Nineteen out of 27 patients (23 liver
and 4 kidney transplant patients) demonstrated some degree of pp65 antigenemia and
DNAemia by both PCR tests. Thirteen patients developed symptomatic infection. Six
patients remained asymptomatic within the follow-up period. All four kidney recipients
were included in the symptomatic patient group.
In our previous studies with liver (II) and kidney (III) transplant patients, the peak viral
loads in the symptomatic HCMV patients were shown to be statistically higher than in
the patients with asymptomatic infection as studied by Cobas Monitor and pp65 assays.
This was also observed in this patient group (IV), and in addition, a statistically signifi-
cant difference was also demonstrated with the results obtained by the developed real-
time assay (53 291 cps/ml versus 1915 cps/ml).
The longitudinal monitoring curves observed by real-time, Cobas Monitor and pp65
antigenemia assays of the two treated liver transplant and one treated kidney transplant
patients were demonstrated (IV: Fig. 2). The follow-up curves of two different PCR tests
and pp65 assay correlated well and significant differences between these methods in the
response to antiviral treatment were not observed. However, the clinical management of
kidney transplant patients was different to that of the liver transplant patients. The liver
transplant patients were frequently monitored from the day of transplantation, having
several negative samples before the HCMV episode. Instead, the kidney transplant pa-
tients already had symptomatic HCMV infection before the first sample was obtained.
In our previous studies (I, II and III) we showed the clinical utility of the Cobas Moni-
tor CMV test in the diagnosis and monitoring of HCMV infections in transplant pa-
tients. In this study (IV) a good correlation between developed real-time HCMV PCR
test and the Cobas Monitor test was shown. However, the real-time assay had advantag-
es over Cobas Monitor test. It was a rapid and labor-saving method in the quantitation
of HCMV DNA. Larger capacity enabled larger numbers of samples to be analysed in a
shorter time. Also, the wider linearity of real-time assay compared with the Cobas test,
made it clinically easier to assess the patients with very low or very high DNAemia. This
proved that real-time PCR assay can be a good alternative method for the diagnosis of
HCMV in clinical laboratories where a large amount of specimens should be analysed
every day.
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